FDA News: 1Q MDUFA III Performance, CDER Priorities and Accomplishments, TVAM Concerns – Drug and Device Digest

FDA BRIEF: Week of March 6, 2017

Image result for MDUFA III image

google

1Q2017 MDUFA III PERFORMANCE METRICS

Metrics for Draft Guidances, PMA, 510(k), IDE posted

PMA

510k

IDE

READ


director

CDER – Moving forward in 2017

Main 2017 Priorities

  • Improving and implementing Informatics Process Management
  • Implementing recent provisions of the 21st Century Cures Act
  • Providing technical assistance to reauthorization of various User Fee bills
  • Executing action plan for combating opioid epidemic
  • Modernizing assessment of manufacturing facilities and mutual reliance initiative with EU
  • Controlling harm from pharmacy compounding

READ

Significant 2016 Achievements

  • Good performance of GDUFA
  • Substantive steps in biosimilar regulation
  • User Fee negotiations
  • Integrating sentinel system with OSE and Safety Surveillance
  • Implementing provisions of various statutes: Sunscreen Innovation Act, Patient-Focused Meetings, Patient-Focused Drug Development meetings in rare disorders

READ


Alert the health care professionals and patients about  Transvascular Autonomic Modulation (TVAM) – an experimental procedure 

TVAM

  • Threading catheter into  venous system, e.g. jugular vein, where balloon attached to inflate to widen vein walls

FDA Unapproved Claim:

  • At least one physician, Dr. Michael Arata‘ – uses TAVM in venous system to treat signs and symptoms of autonomic dysfunction in neurological disorders
  • FDA approval for use only in arteries
  • No FDA review of data supporting safety and effectiveness for intended use in veins

Risk to patients:

  • No clear scientific evidence to support effectiveness – impacting symptom, changing course of health condition, improving quality of life
  • Associated with serious complications: Rupture of balloon, death, blood clots, cranial nerve damage, abdominal bleeding

Scroll to Top